Literature DB >> 24098820

The incubation period of Buruli ulcer (Mycobacterium ulcerans infection).

Jason A Trubiano1, Caroline J Lavender, Janet A M Fyfe, Simone Bittmann, Paul D R Johnson.   

Abstract

INTRODUCTION: Buruli Ulcer (BU) is caused by the environmental microbe Mycobacterium ulcerans. Despite unclear transmission, contact with a BU endemic region is the key known risk factor. In Victoria, Australia, where endemic areas have been carefully mapped, we aimed to estimate the Incubation Period (IP) of BU by interviewing patients who reported defined periods of contact with an endemic area prior to BU diagnosis.
METHOD: A retrospective review was undertaken of 408 notifications of BU in Victoria from 2002 to 2012. Telephone interviews using a structured questionnaire and review of notification records were performed. Patients with a single visit exposure to a defined endemic area were included and the period from exposure to disease onset determined (IP).
RESULTS: We identified 111 of 408 notified patients (27%) who had a residential address outside a known endemic area, of whom 23 (6%) reported a single visit exposure within the previous 24 months. The median age of included patients was 30 years (range: 6 to 73) and 65% were male. 61% had visited the Bellarine Peninsula, currently the most active endemic area. The median time from symptom onset to diagnosis was 71 days (range: 34-204 days). The midpoint of the reported IP range was utilized to calculate a point estimate of the IP for each case. Subsequently, the mean IP for the cohort was calculated at 135 days (IQR: 109-160; CI 95%: 113.9-156), corresponding to 4.5 months or 19.2 weeks. The shortest IP recorded was 32 days and longest 264 days (Figure 1 & 2). IP did not vary for variables investigated.
CONCLUSIONS: The estimated mean IP of BU in Victoria is 135 days (IQR: 109-160 days), 4.5 months. The shortest recorded was IP 34 days and longest 264 days. A greater understanding of BU IP will aid clinical risk assessment and future research.

Entities:  

Mesh:

Year:  2013        PMID: 24098820      PMCID: PMC3789762          DOI: 10.1371/journal.pntd.0002463

Source DB:  PubMed          Journal:  PLoS Negl Trop Dis        ISSN: 1935-2727


Introduction

Mycobacterium ulcerans, a slow growing environmental pathogen [1], causes a necrotizing cutaneous infection with various names but now known internationally as Buruli Ulcer (BU). The mode of transmission remains controversial [2] [3] however the key identifiable risk factor for BU is residence in or contact with a Buruli endemic region. Worldwide, most cases of BU occur in patients who live permanently in endemic areas, and because the mode of transmission is unknown it is generally impossible to estimate the incubation period (IP). The first definitive description of M. ulcerans infection (termed Bairnsdale ulcer in that report) was in Australia in 1948 [1] [4]. Cases have been reported from at least 32 countries, in regions including Africa, Australia, Southeast Asia, China, Central and South America and the Western Pacific [5]. In Victoria, cases have been reported in Gippsland, Phillip Island [6] and the Mornington [7] and Bellarine Peninsulas [8] [9] [10]. In Queensland there is a significant established focus in Far North Queensland [11] [12]. Sporadic cases have been reported in the Northern Territory (NT) [13] and Capricorn Coast of southern Queensland [14]. Single cases have occurred in Western Australia (WA) [15] and New-South Wales (NSW) [16]. Transmission is not reported in South Australia or Tasmania. Few published studies exist dedicated to the incubation of BU. The Uganda Buruli Group estimated that the normal IP was 4–13 weeks [17]. The shortest IP described is 2–3 weeks, in a newborn from Papua New Guinea [18]. Recently within Australia, five patients living outside endemic areas with travel to known endemic regions had reported incubation periods ranging from 2 to 5 months [19]. In Victoria where BU is legally notifiable, diagnosis by Polymerase Chain Reaction (PCR) is centralized and rapid and endemic areas are systematically mapped by members of the WHO Collaborating Centre (WHOCC) in Melbourne. Hence there is a unique opportunity to systematically estimate IP.

Methods

BU has been a legally notifiable infection by treating physicians and laboratories in Victoria since January 2004 and data has been collected systematically and recorded for several years before this. For this investigation we reviewed notifications in the 10-year period 2002 and 2012. The case definition for BU was the presence of a lesion clinically suggestive of M. ulcerans infection together with at least one of; Positive polymerase chain reaction (PCR) for IS2404 [20] [21] [22] Culture and specific identification of M. ulcerans by a Mycobacterium Reference Laboratory. An endemic region was defined as the constant presence of the organism (e.g. M. ulcerans) within a given geographic area or population group [23]. Following literature review and consultation with the Health Department records and those of the WHOCC, endemic regions within Australia were defined and mapped (Table 1, Figure 1 & 2). Significant exposure was defined as greater than one continuous hour in an endemic area and the maximum possible IP considered was two years prior to diagnosis.
Table 1

Regions within Eastern Australia defined as endemic for M.ulcerans.

StateRegions
Victoria (VIC) [[27]] Melbourne Bayside [[7][9]] East Gippsland [[4][1]] Westernport [[7][6][28]] Bellarine Peninsula [[9][10][29][8][2]] Mornington Peninsula [[7][28]]
North Queensland (NQLD) [[14][11][12]] Daintree locality, Daintree River & adjacent coastal lowlands, Mossman Central coast
New South Wales (NSW) [[16]] Southern coastal regions
Figure 1

Geographic representation of Bellarine Peninsula, considered endemic for BU as of 2012.

Bellarine Peninsula – east of line from Geelong to Torquay. Mornington and Westernport – southwest of line from Hampton to Tooradin (including Phillip Island).

Figure 2

Geographic representation of East Gippsland, considered endemic for BU as of 2012.

East Gippsland: East of Sale and south of the great divide.

Geographic representation of Bellarine Peninsula, considered endemic for BU as of 2012.

Bellarine Peninsula – east of line from Geelong to Torquay. Mornington and Westernport – southwest of line from Hampton to Tooradin (including Phillip Island).

Geographic representation of East Gippsland, considered endemic for BU as of 2012.

East Gippsland: East of Sale and south of the great divide. Telephone interview with a structured questionnaire was undertaken with cases or next-of-kin in conjunction with review of medical records and Victorian Department of Health notification record. Data were collected for all geographical exposures to designated BU endemic areas and a map was provided to interviewees to assist them. The duration of exposure was obtained for a single visit and date of onset of symptoms recorded. If a patient was unable to recall a single date of disease exposure, a period of exposure was obtained (maximum one month) and a minimum and maximum IP value for that patient calculated (IP range). If a patient had multiple exposures to known endemic regions within Australia (Northern Territory, Queensland, Western Australia) or overseas and only one occurring within Southern Australia (Victoria and NSW), where possible, variable-number tandem repeat (VNTR) typing was performed on the isolate to identify the region of origin [19] [24] For the 23 patients with a single visit exposure, an IP range was calculated in days and months. The midpoint of the IP range was utilized to calculate a point estimate of the IP for each case. Subsequently, a mean IP for the entire study cohort was calculated. Baseline patient characteristics and data collected were patient residential address, age, sex, location of lesion, duration of endemic exposure, date of first medical attention/form of medical attention, date of when BU first suspected, specimen provided for diagnosis, PCR confirmation, treatment and outcome(s).

Ethics statement

The M. ulcerans investigation was performed as part of an ongoing enhanced surveillance project through the Victorian Department of Health, Victoria, Australia under its responsibilities to record and investigate notifiable diseases. As such interviews of notified cases of BU are routinely conducted, additional ethics approval was not required. No informed patient consent was required.

Statistical analyses

Statistical analyses were performed using STATA version 10.0 (STATA Corporation, College Station, Rx) and PRISM graphpad software 2012.

Results

Of the 408 notifications of BU in the 10-year period 2002–2012, 111 (27%) patients had residential addresses outside the assigned endemic regions, 23 (6%) with single visit exposures and it was from these patients that the IP was estimated. The median age at time of diagnosis of this group was 30 years (Range: 6–73), 65% were male. The residential addresses of all patients were outside established endemic regions (Figure 1 & 2). The endemic areas visited were the Bellarine Peninsula (14; 61%), Phillip Island (3; 13%) and Mornington Peninsula (3; 13%), with single visit exposures to each of Gippsland (VIC), Darwin (NT) and Port Douglas/Mossman (QLD). The duration of exposure was predominately greater than 7 days (60%), but single day exposure was noted in 4 patients (17%) (Table 2).
Table 2

Characteristics of the 23 cases of BU included in the study cohort.

Characteristic (N = 23)No. (%)
Median Age (6–73 years)30 years
0–10 years417
10–18 years626
18–30 years29
30–60 years626
>60 years522
Notification date
2003–2006625
2007–2009417
2010–20121358
Sex
Male1565
Female835
Endemic Area Exposed a
Bellarine1461
Mornington313
Phillip Island313
Gippsland14
NT14
NQLD14
Season of exposure
Summer1461
Autumn417
Winter313
Spring29
Duration of exposure (days)
Single417
1–7626
7–1429
>141148
Mosquito bites during exposure
Yes1357
No835
Unknown29
Open wounds during exposure
Yes14
No2296
Location of lesion
Thigh14
Knee313
Calf730
Ankle730
Shoulder14
Forearm313
Elbow14
Initial clinical presentation b
Papule939
Nodule313
Cellulitis313
Cellulitis & Ulcer313
Ulcer522
Treatment
Surgical treatment alone313
Medical treatment alone417
Combination therapy1670
Time to diagnosis (days) - median
Time from symptom onset to diagnosis71
Time from medical attention to diagnosis35

Three cases had 2 single visit exposures to endemic areas. The causative single visit endemic area exposure was determined via VNTR sequencing.

Clinical presentation was described by patient as the most prominent clinical presentation. Oedematous form was noted in two of the patients with cellulitis.

Three cases had 2 single visit exposures to endemic areas. The causative single visit endemic area exposure was determined via VNTR sequencing. Clinical presentation was described by patient as the most prominent clinical presentation. Oedematous form was noted in two of the patients with cellulitis. The lesions occurred primarily on the extremities, with the lower limbs the most prevalent site (14; 60%). Fifty-one percent of patients recalled mosquito bites within endemic regions, whilst only one patient reported having an open wound. The first medical professional sought for diagnosis and management was a general practitioner from a non-endemic area in 20 of the 23 cases (87%), with the diagnosis of BU suspected in only 17% of cases. The diagnosis of BU was suspected in 3 of 23 (13%) patients on first presentation overall, and 3 of 20 (15%) patients presenting initially to a non-endemic region general practitioner. The median time from symptom onset to PCR confirmed diagnosis was 71 days (range: 23–204 days). The median time from initial medical attention to diagnosis was 35 days (range: 15–103 days) for all patients. Treatment was multimodal (medical management & surgery) in 16 (70%), surgery alone in 3 (13%) and medical alone in 4 (17%). A regime containing rifampicin and one of either clarithromycin or moxifloxacin was used in 17 (94%) patients whose medical management included antibiotic therapy. No episodes of relapse or new infection were reported after treatment completion. Follow-up ranged from 3 months to 9 years (median 24 months). The midpoint of the reported IP range was utilized to calculate a point estimate of the IP for each case (Figure 3a). The IP point estimates for the 23 patients were normally distributed. The mean IP point estimate for the cohort was 135 days (IQR: 109–160 CI 95%: 113.9–156), corresponding to 4.5 months. The shortest incubation period noted was 32 days (1 month) and longest 264 days (9 months). Univariate analysis (Mann-Whitney U) did not identify any significant association between incubation period and sex (p = 0.489), endemic exposure (Bellarine Peninsula vs. other, p = 0.659), location of lesion (arm vs. leg, p = 0.391), age (≤30 vs. ≥31 years, p = 0.644) or the duration of exposure (<7 vs. >7 days, p = 0.207). (Table 3)
Figure 3

The IP for BU infection in the study population.

The IP range (X-axis) for each patient (Y-axis) is demonstrated, arranged from shortest to longest IP. IP range midpoint values are marked as the middle line of each bar.

Table 3

The IP according to variables investigated.

VariableIncubation period (IP)
Min (d/m)Max (d/m)Mean (d)a Range (m)b
Notification date
2003–2006103/4126/431142–9
2007–2009124/4129/51274–6
2010–2012135/6157/61461–9
Age (M = 30)
0–10153/5163/61584–9
10–18102/4116/41092–4
18–30118/4140/51293–7
30–60109/4124/41171–6
>60140/5170/61554–9
Sex
Male135/5143/51391–9
Female112/4131/51222–7
Endemic
Bellarine130/5140/51352–9
Mornington135/5158/61471–9
Phillip Island98/4112/41053–4
Gippsland154/6175/6165N/A
NT140/5170/6155N/A
NQLD106/4109/4108N/A
Duration (d)
Single124/4129/51271–9
1–7122/4131/51274–7
7–14158/6172/61653–9
>14126/5140/51333–6
Lesion locations
Arm69/299/484N/A
Leg109/4140/51254–7

Abbreviations: Bellarine, Bellarine Peninsula; Mornington, Mornington Peninsula; NT, Northern Territory; NQLD, Northern Queensland; X, median; M, mean; d, days; m, months.

Mean: The mean IP for each variable.

Range: Shortest and longest incubation period recorded for specific variable,

The IP for BU infection in the study population.

The IP range (X-axis) for each patient (Y-axis) is demonstrated, arranged from shortest to longest IP. IP range midpoint values are marked as the middle line of each bar. Abbreviations: Bellarine, Bellarine Peninsula; Mornington, Mornington Peninsula; NT, Northern Territory; NQLD, Northern Queensland; X, median; M, mean; d, days; m, months. Mean: The mean IP for each variable. Range: Shortest and longest incubation period recorded for specific variable,

Discussion

Limited published data exists on the incubation period of Buruli ulcer. The Uganda Buruli Group in 1971 proposed an IP of 4–10 weeks in refugees who continued to develop BU following departure from an endemic refugee camp [17], with a rapid cessation of new diagnoses beyond 10 weeks. This may have been an underestimate, as the duration of exposure at the refugee camp is not entirely defined. A study of thirteen cases of BU from Port Moresby identified the shortest known incubation period (2–3 weeks) in a 6-week old baby born in an endemic region [18]. Historical data suggest incubation period estimates of 4–14 weeks [1] [13] [Hayman J, personal communication]. Reports in travelers to endemic regions have also aided research, such as a minimum IP of six weeks in a Nigerian physician working in New York City [25] and 5 months in a traveller from PNG [26]. Molecular typing has been used to identify region-specific M. ulcerans strains, from this the IP for two patients was estimated to be 3 and 7 months [17] and in five travelers from non-endemic areas to QLD and NT a range of 2 to 5 months was estimated [19]. This is the first public health investigation to systematically investigate IP in patients for whom exposure can be reasonably defined. Generally, it is not possible to do this as most patients with BU live permanently in endemic areas, hence time of transmission cannot be determined. Due to the previous systematic mapping documentation of endemic areas in Victoria and interviews with patients obtained through enhanced surveillance after notification we have estimated the mean IP for BU of 135 days, corresponding to 4.5 months or 19.2 weeks. The point estimates appeared normally distributed which suggests, but does not prove, that latency is not a major feature of M. ulcerans infection as we would expect a more right shifted distribution if this were the case, and that inoculum size is relatively similar between patients. The shortest IP noted was 1 month, the longest 9 months. We found no statistical association between individual IPs and other recorded covariables, but acknowledge this may be explained by our small final cohort size. A secondary finding was of that BU is frequently not considered in the differential diagnosis when patients with BU first present to their doctor outside a BU endemic area. Buruli ulcer is an uncommon disease and diagnosis is often delayed when doctors are not familiar with the conditions. Diagnostic delay was not formally assessed with a matched cohort presenting in endemic areas in this investigation, however prolonged time to diagnosis in endemic compared with non-endemic areas has been reported previously [25]. This enhanced surveillance report has several limitations. The small final cohort number of patients in the group with single exposure to endemic areas limited the ability to determine meaningful associations with variables noted in Table 3. Furthermore, patient recall remains an issue particularly for earlier notifications. Nonetheless, the ability to cross-reference the telephone interview with the primary notification and enhanced surveillance forms reduced recall bias. In any investigation of BU, will always be an issue as there is a substantial period between exposure, symptom onset and diagnosis. Furthermore, as the mode of M.ulcerans transmission and exact inoculum size remains unknown, the impact of these variables is not completely understood. Nonetheless, the incubation period appears normally distributed around the point which suggests but does not prove that the inoculum size may have been similar in these 23 patients. We also acknowledge that the IP we have obtained was established in patients from Victoria only, and may or may not be generalizable to tropical Australia or the major endemic foci in sub-Saharan Africa. However our results are broadly similar to previous estimates from Africa and elsewhere.

Conclusion

BU remains a significant cause of morbidity and disease in the developed and developing word. Defining the IP, 4.5 months (R: 1–9 months), provides a reference for future research in M. ulcerans epidemiology, pathogenesis and public health surveillance.
  24 in total

1.  Mycobacterium ulcerans in Australia.

Authors:  A J Radford
Journal:  Aust N Z J Med       Date:  1975-04

2.  Detection of Mycobacterium ulcerans in environmental samples during an outbreak of ulcerative disease.

Authors:  B C Ross; P D Johnson; F Oppedisano; L Marino; A Sievers; T Stinear; J A Hayman; M G Veitch; R M Robins-Browne
Journal:  Appl Environ Microbiol       Date:  1997-10       Impact factor: 4.792

3.  The bairnsdale ulcer.

Authors:  D G Alsop
Journal:  Aust N Z J Surg       Date:  1972-05

4.  Buruli ulcer in New York City.

Authors:  S D Lindo; F Daniels
Journal:  JAMA       Date:  1974-05-27       Impact factor: 56.272

5.  Mycobacterium ulcerans infection: a report of 13 cases at the Port Moresby General Hospital, Papua.

Authors:  I S Reid
Journal:  Med J Aust       Date:  1967-03-04       Impact factor: 7.738

6.  Buruli ulcer disease in travelers and differentiation of Mycobacterium ulcerans strains from northern Australia.

Authors:  Caroline J Lavender; Maria Globan; Paul D R Johnson; Patrick G P Charles; Grant A Jenkin; Niladri Ghosh; Benjamin M Clark; Marianne Martinello; Janet A M Fyfe
Journal:  J Clin Microbiol       Date:  2012-08-08       Impact factor: 5.948

7.  Identification of Mycobacterium ulcerans in the environment from regions in Southeast Australia in which it is endemic with sequence capture-PCR.

Authors:  T Stinear; J K Davies; G A Jenkin; J A Hayman; F Oppedisano; P D Johnson
Journal:  Appl Environ Microbiol       Date:  2000-08       Impact factor: 4.792

8.  A large localized outbreak of Mycobacterium ulcerans infection on a temperate southern Australian island.

Authors:  M G Veitch; P D Johnson; P E Flood; D E Leslie; A C Street; J A Hayman
Journal:  Epidemiol Infect       Date:  1997-12       Impact factor: 2.451

9.  The emergence of Mycobacterium ulcerans infection near Melbourne.

Authors:  P D Johnson; M G Veitch; D E Leslie; P E Flood; J A Hayman
Journal:  Med J Aust       Date:  1996-01-15       Impact factor: 7.738

10.  Epidemiology of Mycobacterium ulcerans infection (Buruli ulcer) at Kinyara, Uganda.

Authors: 
Journal:  Trans R Soc Trop Med Hyg       Date:  1971       Impact factor: 2.184

View more
  23 in total

1.  Mycobacterial skin and soft tissue infection.

Authors:  Shu-Hua Wang; Preeti Pancholi
Journal:  Curr Infect Dis Rep       Date:  2014-11       Impact factor: 3.725

2.  Comparative Genomics Shows That Mycobacterium ulcerans Migration and Expansion Preceded the Rise of Buruli Ulcer in Southeastern Australia.

Authors:  Andrew H Buultjens; Koen Vandelannoote; Conor J Meehan; Miriam Eddyani; Bouke C de Jong; Janet A M Fyfe; Maria Globan; Nicholas J Tobias; Jessica L Porter; Takehiro Tomita; Ee Laine Tay; Torsten Seemann; Benjamin P Howden; Paul D R Johnson; Timothy P Stinear
Journal:  Appl Environ Microbiol       Date:  2018-04-02       Impact factor: 4.792

3.  Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model.

Authors:  Brendon Y Chua; Timothy P Stinear; Kirstie M Mangas; Andrew H Buultjens; Jessica L Porter; Sarah L Baines; Estelle Marion; Laurent Marsollier; Nicholas J Tobias; Sacha J Pidot; Kylie M Quinn; David J Price; Katherine Kedzierska; Weiguang Zeng; David C Jackson
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

4.  Seasonal Patterns of Buruli Ulcer Incidence, Central Africa, 2002-2012.

Authors:  Jordi Landier; Guillaume Constantin de Magny; Andres Garchitorena; Jean-François Guégan; Jean Gaudart; Laurent Marsollier; Philippe Le Gall; Tamara Giles-Vernick; Sara Eyangoh; Arnaud Fontanet; Gaëtan Texier
Journal:  Emerg Infect Dis       Date:  2015-08       Impact factor: 6.883

5.  Complex temporal climate signals drive the emergence of human water-borne disease.

Authors:  Aaron Morris; Rodolphe E Gozlan; Hossein Hassani; Demetra Andreou; Pierre Couppié; Jean-François Guégan
Journal:  Emerg Microbes Infect       Date:  2014-08-06       Impact factor: 7.163

6.  Buruli ulcer in traveler from Suriname, South America, to the Netherlands.

Authors:  William R Faber; Bouke de Jong; Henry J C de Vries; Jim E Zeegelaar; Françoise Portaels
Journal:  Emerg Infect Dis       Date:  2015-03       Impact factor: 6.883

7.  Whole genome comparisons suggest random distribution of Mycobacterium ulcerans genotypes in a Buruli ulcer endemic region of Ghana.

Authors:  Anthony S Ablordey; Koen Vandelannoote; Isaac A Frimpong; Evans K Ahortor; Nana Ama Amissah; Miriam Eddyani; Lies Durnez; Françoise Portaels; Bouke C de Jong; Herwig Leirs; Jessica L Porter; Kirstie M Mangas; Margaret M C Lam; Andrew Buultjens; Torsten Seemann; Nicholas J Tobias; Timothy P Stinear
Journal:  PLoS Negl Trop Dis       Date:  2015-03-31

8.  Mycobacterium ulcerans fails to infect through skin abrasions in a guinea pig infection model: implications for transmission.

Authors:  Heather R Williamson; Lydia Mosi; Robert Donnell; Maha Aqqad; Richard W Merritt; Pamela L C Small
Journal:  PLoS Negl Trop Dis       Date:  2014-04-10

9.  Potential wildlife sentinels for monitoring the endemic spread of human buruli ulcer in South-East australia.

Authors:  Connor Carson; Caroline J Lavender; Kathrine A Handasyde; Carolyn R O'Brien; Nick Hewitt; Paul D R Johnson; Janet A M Fyfe
Journal:  PLoS Negl Trop Dis       Date:  2014-01-30

10.  Experimental infection of the pig with Mycobacterium ulcerans: a novel model for studying the pathogenesis of Buruli ulcer disease.

Authors:  Miriam Bolz; Nicolas Ruggli; Marie-Thérèse Ruf; Meret E Ricklin; Gert Zimmer; Gerd Pluschke
Journal:  PLoS Negl Trop Dis       Date:  2014-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.